LT3151853T - GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE - Google Patents

GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE

Info

Publication number: LT3151853T
Authority: LT; Lithuania
Prior art keywords: gad; treatment; glutamic acid; autoimmune disease; acid decarboxylase
Prior art date: 2014-06-04

Application number

LTEP15802815.9T

Other languages

Lithuanian (lt)

Inventor

Anders Essen-Möller

Johnny Ludvigsson

Original Assignee

Diamyd Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-04

Filing date

2015-06-04

Publication date

2020-08-10

2015-06-04 Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab

2020-08-10 Publication of LT3151853T publication Critical patent/LT3151853T/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
General Engineering & Computer Science (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Nutrition Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LTEP15802815.9T 2014-06-04 2015-06-04 GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE LT3151853T (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE1450678		2014-06-04
SE1451315		2014-11-04
PCT/SE2015/050651 WO2015187087A2 (en)	2014-06-04	2015-06-04	Novel combinations for antigen based therapy

Publications (1)

Publication Number	Publication Date
LT3151853T true LT3151853T (en)	2020-08-10

Family

ID=54767532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15802815.9T LT3151853T (en)	2014-06-04	2015-06-04	GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE

Country Status (20)

Country	Link
US (3)	US20170196949A1 (en)
EP (2)	EP3760224A3 (en)
JP (2)	JP6686007B2 (en)
CN (2)	CN106535926B (en)
AU (3)	AU2015268960B2 (en)
CA (2)	CA2950893C (en)
CY (1)	CY1123160T1 (en)
DK (1)	DK3151853T3 (en)
ES (1)	ES2807787T3 (en)
HU (1)	HUE051151T2 (en)
IL (3)	IL300130B2 (en)
LT (1)	LT3151853T (en)
PL (1)	PL3151853T3 (en)
PT (1)	PT3151853T (en)
RS (1)	RS60581B1 (en)
RU (1)	RU2702632C2 (en)
SI (1)	SI3151853T1 (en)
SM (1)	SMT202000384T1 (en)
WO (1)	WO2015187087A2 (en)
ZA (1)	ZA202204777B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2018133139A1 (en)	2017-01-21	2018-07-26	宁波知明生物科技有限公司	Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome
HUE057216T2 (en) *	2017-09-08	2022-04-28	Diamyd Medical Ab	Genotyping in the treatment and prevention of diabetes
EP4300102A3 (en)	2017-09-08	2024-01-24	Diamyd Medical AB	Improved immunotherapy
EP3749354A4 (en) *	2018-02-05	2021-11-03	Diamyd Medical AB	Novel composition and use thereof
AU2019231706B2 (en) *	2018-03-07	2025-01-23	Atnx Spv, Llc	Compositions and methods for treating hyperproliferative skin disorders
US10500217B2 (en) *	2018-04-30	2019-12-10	Leslie Ray Matthews, M.D., Llc	Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
EP3952859A4 (en) *	2019-04-12	2023-05-10	Loma Linda University	METHODS OF TREATMENT OF NIEMANN-PICK DISEASE TYPE C
US20240245762A1 (en) *	2021-01-13	2024-07-25	University Of Maryland, College Park	Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
CA3223244A1 (en) *	2021-06-17	2022-12-22	Phaim Pharma Ltd	Individualized cell therapy using patient-derived antigen-specific regulatory t cells
WO2023066881A1 (en) *	2021-10-18	2023-04-27	Astrazeneca Ab	Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674978A (en) *	1990-09-21	1997-10-07	The Regents Of The University Of California	Peptides derived from glutamic acid decarboxylase
KR19990063648A (en) *	1995-09-21	1999-07-26	프레드한 아룬디프 에스	Method for providing islet cells with antibodies against glutamic acid decarboxylase and poly (ethylene glycol) conjugates
SE9503379D0 (en) *	1995-09-29	1995-09-29	Synectics Medical Ab	A modified GAD, a method for producing a modified GAD, a method for providing a modified GAD, a peptide and the use of an ordinary and / or a modified GAD
US6884785B2 (en) *	1999-06-17	2005-04-26	The Scripps Research Institute	Compositions and methods for the treatment or prevention of autoimmune diabetes
EP2301553A1 (en) *	2001-11-21	2011-03-30	The Board Of Trustees Of The Leland Stanford Junior University	Polynucleotide therapy
US20050152914A1 (en) *	2003-06-13	2005-07-14	Diamyd, Inc.	Formulation of antigen
AU2005213449A1 (en) *	2004-02-04	2005-08-25	The La Jolla Institute For Allergy And Immunology	Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
EP1755631A2 (en) *	2004-03-03	2007-02-28	Diamyd Medical AB	Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
CA2624615A1 (en) *	2005-10-05	2007-04-19	Bayhill Therapeutics, Inc.	Compositions and methods for treatment of autoimmune disease
DK2118309T3 (en) *	2006-12-29	2015-03-30	Univ Colorado Regents	Diagnostic and therapeutic target for autoimmune diseases and uses thereof
NZ579653A (en) *	2007-03-07	2012-07-27	Uti Limited Partnership	Compositions and methods for the prevention and treatment of autoimmune conditions
WO2008129426A2 (en) *	2007-04-24	2008-10-30	Diamyd Therapeutics Ab	Medicaments and methods to treat autoimmune disease and cancer
ES2627233T3 (en) *	2007-10-12	2017-07-27	Massachusetts Institute Of Technology	Vaccine Nanotechnology
JP2011507511A (en) *	2007-12-19	2011-03-10	ミヴァックディベロップメントアクティエボラグ	Compositions and methods for the treatment of autoimmune and allergic diseases
CN107050456B (en) *	2010-09-28	2022-08-12	加利福尼亚大学董事会	GABA Agonists for the Treatment of Metabolic Syndrome Related Disorders and GABA Combinations for the Treatment or Prevention of Type I Diabetes
WO2012062697A1 (en) *	2010-11-08	2012-05-18	Novartis Ag	Combination therapy for type 1 diabetes
DE102011018499A1 (en) *	2011-04-23	2012-10-25	Emc Microcollections Gmbh	Topical nanoparticle vaccine for the immune stimulation of dendritic cells in the skin
US8735359B2 (en) *	2012-05-24	2014-05-27	Orban Biotech Llc	Combinations of modalities for the treatment of diabetes

2015
- 2015-06-04 CN CN201580040912.4A patent/CN106535926B/en active Active
- 2015-06-04 IL IL300130A patent/IL300130B2/en unknown
- 2015-06-04 US US15/315,557 patent/US20170196949A1/en not_active Abandoned
- 2015-06-04 ES ES15802815T patent/ES2807787T3/en active Active
- 2015-06-04 RS RS20200789A patent/RS60581B1/en unknown
- 2015-06-04 CN CN202210193065.7A patent/CN114504639A/en active Pending
- 2015-06-04 SM SM20200384T patent/SMT202000384T1/en unknown
- 2015-06-04 WO PCT/SE2015/050651 patent/WO2015187087A2/en active Application Filing
- 2015-06-04 LT LTEP15802815.9T patent/LT3151853T/en unknown
- 2015-06-04 DK DK15802815.9T patent/DK3151853T3/en active
- 2015-06-04 HU HUE15802815A patent/HUE051151T2/en unknown
- 2015-06-04 EP EP20172919.1A patent/EP3760224A3/en active Pending
- 2015-06-04 SI SI201531269T patent/SI3151853T1/en unknown
- 2015-06-04 JP JP2017516633A patent/JP6686007B2/en active Active
- 2015-06-04 PT PT158028159T patent/PT3151853T/en unknown
- 2015-06-04 PL PL15802815T patent/PL3151853T3/en unknown
- 2015-06-04 EP EP15802815.9A patent/EP3151853B1/en active Active
- 2015-06-04 RU RU2016150656A patent/RU2702632C2/en active
- 2015-06-04 AU AU2015268960A patent/AU2015268960B2/en active Active
- 2015-06-04 CA CA2950893A patent/CA2950893C/en active Active
- 2015-06-04 CA CA3210184A patent/CA3210184A1/en active Pending
2016
- 2016-11-28 IL IL249250A patent/IL249250B/en active IP Right Grant
2020
- 2020-03-12 IL IL273265A patent/IL273265B2/en unknown
- 2020-04-01 JP JP2020066176A patent/JP2020125300A/en active Pending
- 2020-05-15 AU AU2020203169A patent/AU2020203169B2/en active Active
- 2020-07-28 CY CY20201100694T patent/CY1123160T1/en unknown
2021
- 2021-08-26 US US17/458,018 patent/US20220000995A1/en not_active Abandoned
2022
- 2022-03-23 AU AU2022202003A patent/AU2022202003B2/en active Active
- 2022-04-29 ZA ZA2022/04777A patent/ZA202204777B/en unknown
2024
- 2024-05-17 US US18/667,742 patent/US20240299514A1/en active Pending

Also Published As

Publication number	Publication date
SI3151853T1 (en)	2020-10-30
ZA202204777B (en)	2024-09-25
IL249250B (en)	2020-03-31
CN106535926A (en)	2017-03-22
JP2020125300A (en)	2020-08-20
EP3760224A2 (en)	2021-01-06
JP6686007B2 (en)	2020-04-22
US20220000995A1 (en)	2022-01-06
HUE051151T2 (en)	2021-03-01
US20240299514A1 (en)	2024-09-12
EP3760224A3 (en)	2021-03-31
EP3151853A4 (en)	2018-04-25
AU2015268960A1 (en)	2016-12-15
RU2019129803A (en)	2020-12-14
PT3151853T (en)	2020-07-27
CN106535926B (en)	2022-02-01
EP3151853B1 (en)	2020-05-06
CA3210184A1 (en)	2015-12-10
CY1123160T1 (en)	2021-10-29
AU2020203169A1 (en)	2020-06-04
RU2702632C2 (en)	2019-10-09
IL249250A0 (en)	2017-02-28
AU2022202003A1 (en)	2022-04-14
AU2020203169B2 (en)	2021-12-23
DK3151853T3 (en)	2020-07-27
IL273265A (en)	2020-04-30
AU2015268960B2 (en)	2020-04-09
WO2015187087A2 (en)	2015-12-10
WO2015187087A3 (en)	2016-01-28
RU2016150656A3 (en)	2019-01-25
ES2807787T3 (en)	2021-02-24
CA2950893A1 (en)	2015-12-10
EP3151853A2 (en)	2017-04-12
CA2950893C (en)	2023-10-10
IL273265B2 (en)	2023-06-01
IL300130B2 (en)	2024-05-01
CN114504639A (en)	2022-05-17
RU2016150656A (en)	2018-07-10
IL300130B1 (en)	2024-01-01
RS60581B1 (en)	2020-08-31
JP2017516870A (en)	2017-06-22
AU2022202003B2 (en)	2024-12-12
US20170196949A1 (en)	2017-07-13
SMT202000384T1 (en)	2020-09-10
PL3151853T3 (en)	2020-11-02
IL300130A (en)	2023-03-01

Publication	Publication Date	Title
LT3151853T (en)	2020-08-10	GLUTAMIC ACID DECARBOXYLASE (GAD) FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASE
LT3882250T (en)	2023-05-25	TETRAHYDROPYRANILAMINO-PYROLOPYRIMIDINONE FOR USE IN THE TREATMENT OF DISORDERS CAUSED BY BTK
LT3159409T (en)	2020-01-27	ANTIPRASMIC NUCLEIC ACID FOR THE TREATMENT OF DUSCHENAL MUSCLE DISTROPHY
DK3334422T3 (en)	2020-09-28	USE OF CANNABIDIOLIC ACID IN THE TREATMENT OF EPILEPSY
SG11201704681QA (en)	2017-07-28	Artificial nucleic acid molecules
DK3587417T3 (en)	2022-03-28	1,3-THIAZOL-2-YL-SUBSTITUTED BENZAMIDES
BR112015007494A2 (en)	2017-07-04	dental treatment apparatus.
CL2015000326S1 (en)	2015-06-05	Charger.
DK3229810T3 (en)	2020-08-17	PHOSPHOLIPID-ETHER ANALOGES AS CANCER-DISABLING MEDICINES
LT3390390T (en)	2021-11-25	BIPYRAZOLYLE DERIVATIVES SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP3209331C0 (en)	2023-07-12	OPHTHALMIC SOLUTION
DK3231444T3 (en)	2020-03-16	New treatment
IL251571A0 (en)	2017-06-29	Lepidopteran-active cry1da1 amino acid sequence variant proteins
BR112018005409A2 (en)	2018-10-09	glycodirectional therapy.
DK3302519T3 (en)	2022-02-28	ORNITHODOROS-MOUBATA-COMPLEMENT-INHIBITOR FOR USE IN THE TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
BR112017020745A2 (en)	2018-07-17	patient stratification methods for treatment with retinoic acid α-receptor agonists.
DK3149049T3 (en)	2023-01-23	IL-22 FOR USE IN THE TREATMENT OF METABOLISM DISEASES
LT3191514T (en)	2020-07-10	LIGANTS FOR ENHANCING THE BIOLOGICAL ACTIVITY OF GONADOTROPINS
DK3166473T3 (en)	2020-04-27	ophthalmoscopes
DK3188599T3 (en)	2019-11-25	MEDICAL TREATMENTS BASED ON ANAMORELINE
BR112016026143A2 (en)	2018-08-07	methods and compositions comprising 10-hydroxy-2-decenoic acid.
SMT202200179T1 (en)	2022-07-21	AQUEOUS OPHTHALMIC COMPOSITION.
BR112017011897A2 (en)	2018-07-03	fibrosis treatment methods
DK3125867T3 (en)	2021-12-06	HYPEROSMOLAR HYALURONIC ACID COMPOSITION
LT3364975T (en)	2021-09-10	COMBINATION OF TRASODONE AND GABAPENTIN FOR THE TREATMENT OF PAIN